MET and nasopharyngeal carcinoma: These results enhance our knowledge of the mechanisms underlying aberrant activation of the MET pathway in NPC, and may help to establish MET as a novel prognostic biomarker and therapeutic target for the treatment of subgroups of patients with locoregionally advanced NPC.